Zacks Research Comments on Zoetis’ Q1 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Zacks Research dropped their Q1 2025 earnings per share estimates for Zoetis in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.39 per share for the quarter, down from their previous estimate of $1.45. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q2 2025 earnings at $1.60 EPS, Q3 2025 earnings at $1.62 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.07 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.66 EPS, Q3 2026 earnings at $1.69 EPS and FY2027 earnings at $6.97 EPS.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion.

Several other equities research analysts have also issued reports on the stock. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $215.90.

Zoetis Stock Performance

Shares of ZTS opened at $170.34 on Friday. Zoetis has a one year low of $144.80 and a one year high of $200.33. The firm has a market capitalization of $76.28 billion, a P/E ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business has a fifty day moving average of $166.72 and a 200 day moving average of $176.83.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after purchasing an additional 120,158 shares in the last quarter. State Street Corp raised its holdings in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after buying an additional 95,856 shares during the period. Geode Capital Management LLC lifted its stake in shares of Zoetis by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock worth $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Finally, Wellington Management Group LLP grew its stake in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by insiders.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.